AtriCure (NASDAQ:ATRC) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of AtriCure (NASDAQ:ATRC) from a hold rating to a strong-buy rating in a report published on Wednesday morning,Zacks reports.

Several other equities analysts also recently issued reports on ATRC. Citizens Jmp raised their price target on shares of AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 21st. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Freedom Capital downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $70.00 target price (up from $60.00) on shares of AtriCure in a research report on Wednesday. Finally, Needham & Company LLC raised their target price on AtriCure from $64.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $61.80.

AtriCure Stock Performance

NASDAQ:ATRC opened at $61.28 on Wednesday. The stock’s 50-day moving average is $56.62 and its 200-day moving average is $38.63. AtriCure has a 1-year low of $25.36 and a 1-year high of $66.02. The company has a current ratio of 4.33, a quick ratio of 3.19 and a debt-to-equity ratio of 0.11. The stock has a market cap of $3.12 billion, a P/E ratio of 204.27 and a beta of 1.23.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a net margin of 2.52% and a return on equity of 4.01%. The business had revenue of $154.45 million during the quarter, compared to analyst estimates of $151.05 million. Equities research analysts anticipate that AtriCure will post 0.29 earnings per share for the current year.

Insider Activity at AtriCure

In other AtriCure news, insider Karl Dahlquist sold 9,370 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. This represents a 9.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Salvatore Privitera sold 8,404 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the transaction, the insider owned 134,341 shares of the company’s stock, valued at approximately $8,732,165. The trade was a 5.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,026 shares of company stock worth $2,172,263 over the last ninety days. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently bought and sold shares of ATRC. Allworth Financial LP increased its stake in shares of AtriCure by 372.8% in the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 1,204 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of AtriCure by 43.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company’s stock valued at $158,000 after acquiring an additional 1,205 shares during the period. Harbor Investment Advisory LLC bought a new position in AtriCure during the second quarter worth $40,000. Sterling Capital Management LLC boosted its stake in AtriCure by 841.1% during the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock worth $93,000 after acquiring an additional 1,472 shares in the last quarter. Finally, Fulcrum Asset Management LLP bought a new position in AtriCure during the third quarter worth $92,000. Institutional investors own 99.11% of the company’s stock.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
• Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
• Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
• Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
• Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.